ICAD Stock Overview
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States.
No risks detected for ICAD from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.00|
|52 Week High||US$17.90|
|52 Week Low||US$2.91|
|1 Month Change||4.71%|
|3 Month Change||-10.91%|
|1 Year Change||-77.22%|
|3 Year Change||-35.28%|
|5 Year Change||-5.21%|
|Change since IPO||-92.10%|
Recent News & Updates
Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|ICAD||US Healthcare Services||US Market|
Return vs Industry: ICAD underperformed the US Healthcare Services industry which returned -39.8% over the past year.
Return vs Market: ICAD underperformed the US Market which returned -20.8% over the past year.
|ICAD Average Weekly Movement||11.7%|
|Healthcare Services Industry Average Movement||12.7%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ICAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ICAD's weekly volatility (12%) has been stable over the past year.
About the Company
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment.
iCAD Fundamentals Summary
|ICAD fundamental statistics|
Is ICAD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ICAD income statement (TTM)|
|Cost of Revenue||US$8.94m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.52|
|Net Profit Margin||-40.43%|
How did ICAD perform over the long term?See historical performance and comparison
Is ICAD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ICAD?
Other financial metrics that can be useful for relative valuation.
|What is ICAD's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ICAD's PS Ratio compare to its peers?
|ICAD PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
TRHC Tabula Rasa HealthCare
Price-To-Sales vs Peers: ICAD is expensive based on its Price-To-Sales Ratio (3.1x) compared to the peer average (2.5x).
Price to Earnings Ratio vs Industry
How does ICAD's PE Ratio compare vs other companies in the US Healthcare Services Industry?
Price-To-Sales vs Industry: ICAD is good value based on its Price-To-Sales Ratio (3.1x) compared to the US Healthcare Services industry average (3.2x)
Price to Sales Ratio vs Fair Ratio
What is ICAD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3.1x|
|Fair PS Ratio||6.3x|
Price-To-Sales vs Fair Ratio: ICAD is good value based on its Price-To-Sales Ratio (3.1x) compared to the estimated Fair Price-To-Sales Ratio (6.3x).
Share Price vs Fair Value
What is the Fair Price of ICAD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ICAD's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICAD's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is iCAD forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score5/6
Future Growth Score 5/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ICAD is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ICAD is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ICAD is expected to become profitable in the next 3 years.
Revenue vs Market: ICAD's revenue (27.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: ICAD's revenue (27.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ICAD's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has iCAD performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ICAD is currently unprofitable.
Growing Profit Margin: ICAD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ICAD is unprofitable, and losses have increased over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare ICAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICAD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.7%).
Return on Equity
High ROE: ICAD has a negative Return on Equity (-30.05%), as it is currently unprofitable.
Discover strong past performing companies
How is iCAD's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ICAD's short term assets ($47.9M) exceed its short term liabilities ($14.5M).
Long Term Liabilities: ICAD's short term assets ($47.9M) exceed its long term liabilities ($631.0K).
Debt to Equity History and Analysis
Debt Level: ICAD is debt free.
Reducing Debt: ICAD currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICAD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ICAD has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 11.5% each year.
Discover healthy companies
What is iCAD current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICAD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICAD's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ICAD has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stacey Stevens (53 yo)
Ms. Stacey M. Stevens is Chief Executive Officer and Director at iCAD, Inc. since March 1, 2022. She has been President of iCAD, Inc. since March 28, 2019. Ms. Stevens served as Executive Vice President an...
CEO Compensation Analysis
Compensation vs Market: Stacey's total compensation ($USD773.41K) is about average for companies of similar size in the US market ($USD760.83K).
Compensation vs Earnings: Stacey's compensation has increased whilst the company is unprofitable.
Experienced Management: ICAD's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Experienced Board: ICAD's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
iCAD, Inc.'s employee growth, exchange listings and data sources
- Name: iCAD, Inc.
- Ticker: ICAD
- Exchange: NasdaqCM
- Founded: 1984
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: US$100.727m
- Shares outstanding: 25.18m
- Website: https://www.icadmed.com
Number of Employees
- iCAD, Inc.
- 98 Spit Brook Road
- Suite 100
- New Hampshire
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/30 00:00|
|End of Day Share Price||2022/06/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.